Michael Højby Rasmussen

Summary

Affiliation: Novo Nordisk A/S
Country: Denmark

Publications

  1. ncbi Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile
    Michael Højby Rasmussen
    Departments of Medical and Science, Novo Nordisk A S, DK 2880 Bagsvaerd, Denmark
    J Clin Endocrinol Metab 95:3411-7. 2010
  2. ncbi Multiple doses of pegylated long-acting growth hormone are well tolerated in healthy male volunteers and possess a potential once-weekly treatment profile
    Michael Højby Rasmussen
    Global Development, Novo Nordisk A S, Novo Alle, Bagsvaerd, Denmark
    Clin Endocrinol (Oxf) 73:769-76. 2010
  3. ncbi Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency
    Esben Søndergaard
    Aarhus University Hospital, DK 8000, Aarhus C, Denmark
    J Clin Endocrinol Metab 96:681-8. 2011

Collaborators

Detail Information

Publications3

  1. ncbi Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile
    Michael Højby Rasmussen
    Departments of Medical and Science, Novo Nordisk A S, DK 2880 Bagsvaerd, Denmark
    J Clin Endocrinol Metab 95:3411-7. 2010
    ..NNC126-0083 is a pegylated rhGH developed with the aim of reducing serum clearance and thereby prolonging the exposure leading to once-weekly sc administration...
  2. ncbi Multiple doses of pegylated long-acting growth hormone are well tolerated in healthy male volunteers and possess a potential once-weekly treatment profile
    Michael Højby Rasmussen
    Global Development, Novo Nordisk A S, Novo Alle, Bagsvaerd, Denmark
    Clin Endocrinol (Oxf) 73:769-76. 2010
    ..The current study examined safety, tolerability, pharmacokinetic and pharmacodynamic response parameters after single and multiple doses of a long-acting rhGH preparation (NNC126-0083)...
  3. ncbi Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency
    Esben Søndergaard
    Aarhus University Hospital, DK 8000, Aarhus C, Denmark
    J Clin Endocrinol Metab 96:681-8. 2011
    ..NNC126-0083 is a pegylated rhGH developed for once-weekly administration...